z-logo
open-access-imgOpen Access
A Successful Chemoembolization of a Retroperitoneal Soft Tissue Sarcoma: A Case Report
Author(s) -
David Filho Waldec Jorge,
Uchiyama Angel Ayumi Tome,
Marchon Catarina,
Lopes Letícia Maria Duarte,
Baccarin Ana Luísa de Castro,
de Fina Bruna,
dos Santos Ricardo Virgílio,
Galastri Francisco Leonardo
Publication year - 2021
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000520381
Subject(s) - case report
Retroperitoneal sarcomas are rare entities. They have a tendency of growing slowly, rendering the patient apparently healthy for long periods of time, before diagnosis. Besides, they have a worse prognosis than sarcomas arising in extremities, with a higher local recurrence rate and lower 5-year survival rate. We describe a case of a 71-year-old male patient, who had a very well succeeded treatment of a large retroperitoneal sarcoma with the combination of chemoembolization, systemic chemotherapy, surgery, and radiation therapy. Initially, it was noticed in an incidental way he had a large retroperitoneal mass (15 cm × 10 cm × 9.2 cm) through magnetic resonance, when he was 63. The case was considered inoperable by the treating physicians. After neoadjuvant therapy, the residual tumor could be completely excised by the responsible surgeon. With a follow-up of >5 years, since the end of treatment, the patient remains in complete remission and, probably, cured from his illness. Large retroperitoneal sarcomas are still a great challenge for oncologists. According to the medical literature, chemoembolization can benefit some patients, but most of them in a palliative setting. In our report, we believe its contribution was critical for a great outcome. In selected cases, it is possible this procedure may be an additional therapeutic modality, as part of a multidisciplinary approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here